HBC Hofseth Biocare

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION

Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally and has held 1,747,976 shares indirectly through the Bonafide fund. Redemption of the fund has led to transfer of his indirect holdings to his personal account, and hence Mr. Baldegger now personally holds 3,247,976 shares and zero indirect ownership in HBC, equal to approximately 0.82 % of the total outstanding A-shares with voting rights.

For further information, contact:

Jon Olav Ødegård, CEO of Hofseth BioCare ASA

Phone:

E-mail:

This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.



EN
20/02/2025

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding (i) the completion of a private placement (the "Private Placement") of new shares in the Company the "Offer Shares"), the completion of which by delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") is subject to, among other things, an extraordinary general meeting (the "EGM") resolving to issue the T2 Offer Shares in the Private Placement and (ii) a potential subsequent repair offering which i...

October 30, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Mandatory Notification of Trade

Hofseth BioCare ASA: Mandatory Notification of Trade Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. In the Private Placement, Hofseth International AS was allocated 28,666,666 new shares at the subscription price of NOK 1.80. Please refer to the attached notification form for further information. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19. For furth...

October 27, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Ex. Subsequent Offering Today

Ex. Subsequent Offering Today NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 relating to a contemplated subsequent offering of up to 16,666,666 new shares directed towards certain eligible shareholders...

October 27, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares i...

October 27, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Disclosures of Large Shareholdings

Hofseth BioCare ASA: Disclosures of Large Shareholdings Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. The following shareholders of the Company have, on 27 October 2025, been allocated new shares in the Private Placement which implies that their holdings have surpassed a notifiable threshold: Guy Urquhart have subscribed for 55,444,444 new shares in the Private Placement. Following this, Guy Urquhart holds 55,444,444...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch